Grundläggande statistik
| CIK | 1447362 |
SEC Filings
All companies that sell securities in the United States must register with the Securities and Exchange Commission (SEC) and file reports on a regular basis.
These reports include company annual reports (10K, 10Q), news updates (8K), investor presentations (found in 8Ks), insider trades (form 4), ownership reports (13D, and 13G), and reports related to the specific securities sold, such as registration statements and prospectus. This page shows recent SEC filings related to Castle Biosciences, Inc.
SEC Filings (Chronological Order)
Denna sida innehåller en komplett, kronologisk lista över SEC-arkiveringar, exklusive ägande-arkiveringar som vi tillhandahåller på andra ställen.
| May 29, 2026 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 28, 2026 Castle Biosciences, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38984 77-0701774 (State or other jurisdiction of incorporation) (Commission F |
|
| May 6, 2026 |
SECOND AMENDMENT TO LEASE AGREEMENT Exhibit 10.3 SECOND AMENDMENT TO LEASE AGREEMENT THIS SECOND AMENDMENT TO LEASE AGREEMENT (this “Amendment”) is made and entered into as of the date of the last party to sign below (the “Effective Date”), by and between ACA CONCOURSE EAST UNIT 3 LLC, a Delaware limited liability company (“Landlord”) and CASTLE BIOSCIENCES, INC., a Delaware corporation (“Tenant”). Landlord and Tenant are sometimes |
|
| May 6, 2026 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2026 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 0 |
|
| May 6, 2026 |
exhibit992q12026 ©2026 Castle Biosciences 1 Empowering people, informing care decisions May 2026 ©2026 Castle Biosciences 2 Disclaimers Forward Looking Statements This presentation contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, which are subject to the “safe harbor” created by those sections. |
|
| May 6, 2026 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 6, 2026 Castle Biosciences, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38984 77-0701774 (state or other jurisdiction of incorporation) (Commission Fi |
|
| May 6, 2026 |
Exhibit 99.1 Castle Biosciences Reports First Quarter 2026 Results Delivered Q1 2026 revenue of $83.7 million Q1 2026 total test reports for our core revenue drivers (DecisionDx®-Melanoma, TissueCypher®) increased 36% over Q1 2025 Raising full-year 2026 revenue guidance to $345-355 million from $340-350 million Conference call and webcast today at 4:30 p.m. ET FRIENDSWOOD, Texas – May 6, 2026 – Ca |
|
| May 6, 2026 |
Exhibit 10.2 LEASE AGREEMENT Between FAROS ACA RE LLC and CASTLE BIOSCIENCES, INC. Unit 1, Nova Place Concourse, Pittsburgh, Pennsylvania Contents Article I - Premises and Term 1 Section 1.1 - Description of Premises 1 Section 1.2 - Interests Granted with the Premises. 2 Section 1.3 - Term 2 Section 1.4 - Reserved Rights 3 Section 1.5 - Extension Option 3 Article II - Rent 4 Section 2.1 - Definiti |
|
| May 6, 2026 |
FIRST AMENDMENT TO OFFICE LEASE AGREEMENT Exhibit 10.1 FIRST AMENDMENT TO OFFICE LEASE AGREEMENT THIS FIRST AMENDMENT TO OFFICE LEASE AGREEMENT (this “First Amendment”) is made and entered into by and between PERIMETER GATEWAY PORTFOLIO LLC, a Delaware limited liability company (“Landlord”), and CASTLE BIOSCIENCES, INC., a Delaware corporation (“Tenant”), effective as of 3/5/2026, 2026 (the “Effective Date”). W I T N E S S E T H: WHEREAS, |
|
| April 8, 2026 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No.) Filed by the Registrant ☒ Filed by a party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)( |
|
| April 8, 2026 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No.) Filed by the Registrant ☒ Filed by a party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Defini |
|
| April 8, 2026 |
LetterfromourChiefExecutiveOicer Dear Fellow Stockholders, 2025 was a year of meaningful progress for Castle, marked by strong performance and continued advancement toward our mission of improving health through innovative tests that guide patient care. |
|
| February 26, 2026 |
Exhibit 21.1 CASTLE BIOSCIENCES, INC. SUBSIDIARIES OF THE REGISTRANT Name of Subsidiary State of Incorporation AltheaDx, Inc. Delaware Cernostics, Inc. Delaware Myriad myPath, LLC Delaware Friendswood Parkway Plaza LLC Texas |
|
| February 26, 2026 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-38 |
|
| February 26, 2026 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 26, 2026 Castle Biosciences, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38984 77-0701774 (state or other jurisdiction of incorporation) (Commiss |
|
| February 26, 2026 |
exhibit992q42025corporat ©2026 Castle Biosciences 1 Empowering people, informing care decisions February 2026 ©2026 Castle Biosciences 2 Disclaimers Forward Looking Statements This presentation contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, which are subject to the “safe harbor” created by those sections. |
|
| February 26, 2026 |
Exhibit 107 Calculation of Filing Fee Table Form S-8 Castle Biosciences, Inc. Table 1: Newly Registered Securities Security Type Security Class Title Fee Calculation Rule Amount Registered Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee 1 Equity 2019 Equity Incentive Plan, Common Stock, $0.001 per share Other 1,484,315 $32.31 $47,958,21 |
|
| February 26, 2026 |
Exhibit 99.1 Castle Biosciences Reports Fourth Quarter and Full–Year 2025 Results 2025 total test reports for our core revenue drivers (DecisionDx®-Melanoma, TissueCypher®) increased 37% over 2024 Exceeded 2025 guidance with full-year revenue of $344 million Conference call and webcast today at 4:30 p.m. ET FRIENDSWOOD, Texas – Feb. 26, 2026 – Castle Biosciences, Inc. (Nasdaq: CSTL), a company imp |
|
| February 26, 2026 |
As filed with the Securities and Exchange Commission on February 26, 2026 As filed with the Securities and Exchange Commission on February 26, 2026 Registration No. |
|
| January 13, 2026 |
exhibit992cstlq42025prel ©2026 Castle Biosciences 1 Empowering people, informing care decisions Preliminary Unaudited Fourth Quarter and Year-End Results 2025 January 2026 ©2026 Castle Biosciences 2 Disclaimers Forward-Looking Statements This presentation contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, which are subject to the “safe harbor” created by those sections. |
|
| January 13, 2026 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 11, 2026 Castle Biosciences, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38984 77-0701774 (state or other jurisdiction of incorporation) (Commissi |
|
| January 13, 2026 |
Exhibit 99.1 Castle Biosciences Announces Preliminary Unaudited Fourth Quarter and Full–Year 2025 Results 2025 total revenue expected to exceed $340 million, above the previously guided range of $327-335 million 2025 total test reports for our core revenue drivers (DecisionDx®-Melanoma, TissueCypher®) increased 37% over 2024 Year-end 2025 cash, cash equivalents and marketable investment securities |
|
| November 3, 2025 |
As filed with the Securities and Exchange Commission on November 3, 2025 As filed with the Securities and Exchange Commission on November 3, 2025 Registration No. |
|
| November 3, 2025 |
Exhibit 99.1 Castle Biosciences Reports Third Quarter 2025 Results Delivered Q3 2025 revenue of $83 million Q3 2025 non-dermatologic revenue increased by 67% over Q3 2024 Q3 2025 total test reports for our core revenue drivers (DecisionDx®-Melanoma, TissueCypher®) increased 36% over Q3 2024 Raising full-year 2025 revenue guidance to $327-335 million from $310-320 million Announced launch of Advanc |
|
| November 3, 2025 |
Exhibit 107 Calculation of Filing Fee Table Form S-8 Castle Biosciences, Inc. Table 1: Newly Registered Securities Security Type Security Class Title Fee Calculation Rule Amount Registered Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee 1 Equity 2022 Inducement Plan, Common Stock, $0.001 per share Other 700,000 $24.32 $17,024,000.00 $0. |
|
| November 3, 2025 |
Exhibit 10.2 CASTLE BIOSCIENCES, INC. 2022 INDUCEMENT PLAN ADOPTED BY THE COMPENSATION COMMITTEE: DECEMBER 22, 2022 AMENDED AND RESTATED BY THE COMPENSATION COMMITTEE: NOVEMBER 3, 2023 AMENDED AND RESTATED BY THE COMPENSATION COMMITTEE: AUGUST 5, 2025 1. GENERAL. (a) Eligible Award Recipients. The only persons eligible to receive grants of Awards under this Plan are individuals who satisfy the sta |
|
| November 3, 2025 |
Exhibit 10.1 Castle Biosciences, Inc. Non-Employee Director Compensation Policy Adopted: June 8, 2019 Amended: January 28, 2021 Amended January 24, 2022 Amended: January 31, 2023 Amended: May 31, 2024 Amended: May 22, 2025 Amended: August 5, 2025 (the “Effective Date”) Each member of the Board of Directors (the “Board”) of Castle Biosciences, Inc. (the “Company”) who is a non-employee director of |
|
| November 3, 2025 |
exhibit992q32025 ©2025 Castle Biosciences 1 Empowering people, informing care decisions November 2025 ©2025 Castle Biosciences 2 Disclaimers Forward-Looking Statements This presentation contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, which are subject to the “safe harbor” created by those sections. |
|
| November 3, 2025 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Numbe |
|
| November 3, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 3, 2025 Castle Biosciences, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38984 77-0701774 (state or other jurisdiction of incorporation) (Commissi |
|
| October 2, 2025 |
144 0001239501 XXXXXXXX LIVE 0001447362 Castle Biosciences, Inc. 001-38984 505 S. Friendswood Drive Suite 401 Friendswood TX 77546 1-866-788-9007 Derek Maetzold Officer Common Goldman Sachs & Co. LLC 200 West Street New York NY 10282 4017 89297.91 29008281 10/02/2025 NASD Common 08/09/2024 Acquired as compensation - Performance Awards Issuer N 4017 08/09/2024 Compensation N Derek Maetzold 505 S. F |
|
| August 27, 2025 |
144 0001856565 XXXXXXXX LIVE 0001447362 Castle Biosciences, Inc. 001-38984 505 S. Friendswood Drive, Suite 401 Friendswood TX 77546 866-788-9007 Kristen M. Oelschlager Officer Common Stock J.P. Morgan Securities LLC 390 Madison Avenue, 6th Floor New York NY 10017 18007 384449.45 29008281 08/27/2025 NASDAQ Common Stock 03/04/2025 Restricted Stock Unit Issuer N 10171 03/04/2025 Compensation Common S |
|
| August 27, 2025 |
144 0001856565 XXXXXXXX LIVE 0001447362 Castle Biosciences, Inc. 001-38984 505 S. Friendswood Drive, Suite 401 Friendswood TX 77546 866-788-9007 Kristen M. Oelschlager Officer Common Stock J.P. Morgan Securities LLC 390 Madison Avenue, 6th Floor New York NY 10017 25355 541329 29008281 08/27/2025 NASDAQ Common Stock 08/09/2024 Restricted Stock Unit Issuer N 7837 08/09/2024 Compensation Common Stock |
|
| August 8, 2025 |
AMENDED AND RESTATED BYLAWS OF CASTLE BIOSCIENCES, INC. (A DELAWARE CORPORATION) ARTICLE I OFFICES Exhibit 3.1 AMENDED AND RESTATED BYLAWS OF CASTLE BIOSCIENCES, INC. (A DELAWARE CORPORATION) ARTICLE I OFFICES Section 1. Registered Office. The registered office of the corporation in the State of Delaware and the name of the corporation’s registered agent at such address shall be as set forth in the certificate of incorporation of the corporation (as the same may be amended and/or restated from |
|
| August 8, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 5, 2025 Castle Biosciences, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38984 77-0701774 (state or other jurisdiction of incorporation) (Commission |
|
| August 4, 2025 |
, 2025, by and between the Registrant and Perimeter Gateway Portfolio LLC. Exhibit 10.3 OFFICE LEASE AGREEMENT FOR TWO SCOTTSDALE LANDING PERIMETER GATEWAY PORTFOLIO LLC, a Delaware limited liability company, as Landlord and CASTLE BIOSCIENCES, INC., a Delaware corporation, as Tenant Dated: 05/14/2025, 2025 OFFICE LEASE AGREEMENT THIS OFFICE LEASE AGREEMENT is made and entered into as of the Effective Date by and between PERIMETER GATEWAY PORTFOLIO LLC, a Delaware limite |
|
| August 4, 2025 |
greement, dated June 20, 2025 by and between the Registrant and Frank Stokes. Exhibit 10.5 C-Suite and SVP Form AMENDED PARTICIPATION AGREEMENT Name: Frank Stokes Section 1. ELIGIBILITY. You have been designated as eligible to participate in the Castle Biosciences, Inc. Severance and Change in Control Plan (the “Plan”), a copy of which is attached to this Amended Participation Agreement (the “Participation Agreement”). Capitalized terms not explicitly defined in this Partic |
|
| August 4, 2025 |
Exhibit 99.1 Castle Biosciences Reports Second Quarter 2025 Results Delivered Q2 2025 revenue of $86 million Q2 2025 total test reports for our core revenue drivers (DecisionDx®-Melanoma, TissueCypher®) increased 33% over Q2 2024 Raising full-year 2025 revenue guidance range to $310-320 million from $287-297 million Conference call and webcast today at 4:30 p.m. ET FRIENDSWOOD, Texas - August 4, 2 |
|
| August 4, 2025 |
greement, dated June 20, 2025 by and between the Registrant and Kristen Oelschlager. Exhibit 10.7 C-Suite and SVP Form AMENDED PARTICIPATION AGREEMENT Name: Kristen Oelschlager Section 1. ELIGIBILITY. You have been designated as eligible to participate in the Castle Biosciences, Inc. Severance and Change in Control Plan (the “Plan”), a copy of which is attached to this Amended Participation Agreement (the “Participation Agreement”). Capitalized terms not explicitly defined in this |
|
| August 4, 2025 |
Non-Employee Director Compensation Policy, as amended effective May 22, 2025. Exhibit 10.4 Castle Biosciences, Inc. Non-Employee Director Compensation Policy Adopted: June 8, 2019 Amended: January 28, 2021 Amended January 24, 2022 Amended: January 31, 2023 Amended: May 31, 2024 Amended: May 22, 2025 (the “Effective Date”) Each member of the Board of Directors (the “Board”) of Castle Biosciences, Inc. (the “Company”) who is a non-employee director of the Company (each such m |
|
| August 4, 2025 |
exhibit992q22025 ©2025 Castle Biosciences 1 Empowering people, informing care decisions August 2025 ©2025 Castle Biosciences 2 Disclaimers Forward-Looking Statements This presentation contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, which are subject to the “safe harbor” created by those sections. |
|
| August 4, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 4, 2025 Castle Biosciences, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38984 77-0701774 (state or other jurisdiction of incorporation) (Commission |
|
| August 4, 2025 |
greement, dated June 20, 2025 by and between the Registrant and Toby Juvenal. Exhibit 10.6 C-Suite and SVP Form AMENDED PARTICIPATION AGREEMENT Name: Toby Juvenal Section 1. ELIGIBILITY. You have been designated as eligible to participate in the Castle Biosciences, Inc. Severance and Change in Control Plan (the “Plan”), a copy of which is attached to this Amended Participation Agreement (the “Participation Agreement”). Capitalized terms not explicitly defined in this Partic |
|
| August 4, 2025 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 00 |
|
| May 23, 2025 |
Amended and Restated Certificate of Incorporation of Castle Biosciences, Inc. Exhibit 3.1 AMENDED AND RESTATED CERTIFICATE OF INCORPORATION OF CASTLE BIOSCIENCES, INC. Derek Maetzold hereby certifies that: ONE: He is the duly elected and acting President and Chief Executive Officer of Castle Biosciences, Inc., a Delaware corporation. TWO: The date of filing of said corporation’s original certificate of incorporation with the Delaware Secretary of State was September 12, 200 |
|
| May 23, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 22, 2025 Castle Biosciences, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38984 77-0701774 (State or other jurisdiction of incorporation) (Commission F |
|
| May 5, 2025 |
©2025 Castle Biosciences 1 Empowering people, informing care decisions May 2025 ©2025 Castle Biosciences 2 Disclaimers Forward-Looking Statements This presentation contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, which are subject to the “safe harbor” created by those sections. |
|
| May 5, 2025 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 0 |
|
| May 5, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 5, 2025 Castle Biosciences, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38984 77-0701774 (state or other jurisdiction of incorporation) (Commission Fi |
|
| May 5, 2025 |
exhibit992q12025earnings ©2025 Castle Biosciences 1 Empowering people, informing care decisions First Quarter 2025 May 5, 2025 ©2025 Castle Biosciences 2 Disclaimers Forward-Looking Statements This presentation contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, which are subject to the “safe harbor” created by those sections. |
|
| May 5, 2025 |
Exhibit 99.1 Castle Biosciences Reports First Quarter 2025 Results Q1 2025 revenue increased 21% over Q1 2024 to $88 million Q1 2025 total test reports for our core revenue drivers (DecisionDx®-Melanoma, DecisionDx®-SCC, TissueCypher®) increased 33% over Q1 2024 Raising full-year 2025 revenue guidance to $287-297 million from $280-295 million Conference call and webcast today at 4:30 p.m. ET FRIEN |
|
| May 5, 2025 |
Exhibit 10.1 CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL. CONSENT AND FIRST AMENDMENT TO LOAN AND SECURITY AGREEMENT This CONSENT AND FIRST AMENDMENT TO LOAN AND SECURITY AGREEMENT (this “Agreement”) is entered into as of April 4, 2025, by a |
|
| May 5, 2025 |
by and between the Registrant and Tannos Land Holdings III, LLC Exhibit 10.2 COMMERCIAL LEASE AMENDMENT USE OF THIS FORM BY PERSONS WHO ARE NOT MEMBERS OF THE TEXAS ASSOCIATION OF REALTORS®, INC. IS NOT AUTHORIZED. ©Texas Association of REALTORS®, Inc. 2022 AMENDMENT TO THE COMMERCIAL LEASE BETWEEN THE UNDERSIGNED PARTIES CONCERNING THE LEASED PREMISES AT 505 S Friendswood Dr 313, Friendswood, TX 77546 Effective on March 7, 2025 , Landlord and Tenant amend the |
|
| April 9, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No.) Filed by the Registrant ☒ Filed by a party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)( |
|
| April 9, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No.) Filed by the Registrant ☒ Filed by a party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Defini |
|
| April 9, 2025 |
20 24 ANNUAL REPORTDear Fellow Stockholders, 2024 was another year of strength for Castle. |
|
| March 28, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No.) Filed by the Registrant ☒ Filed by a party other than the Registrant ☐ Check the appropriate box: ☒ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)( |
|
| February 27, 2025 |
Subsidiaries of the Registrant. Exhibit 21.1 CASTLE BIOSCIENCES, INC. SUBSIDIARIES OF THE REGISTRANT Name of Subsidiary State of Incorporation AltheaDx, Inc. Delaware Cernostics, Inc. Delaware Myriad myPath, LLC Delaware Castle Narnia Way Real Estate Holding 1, LLC Texas |
|
| February 27, 2025 |
Exhibit 99.1 Castle Biosciences Reports Fourth Quarter and Full-Year 2024 Results Full-year 2024 revenue of $332 million, an increase of 51% compared to 2023 and above previously reported guidance Delivered 96,071 total test reports in 2024, an increase of 36% compared to 2023 Year-end 2024 cash, cash equivalents and marketable investment securities of $293 million, a $50 million increase compared |
|
| February 27, 2025 |
©2025 Castle Biosciences 1 Empowering people, informing care decisions February 2025 ©2025 Castle Biosciences 2 Disclaimers Forward-Looking Statements This presentation contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, which are subject to the “safe harbor” created by those sections. |
|
| February 27, 2025 |
©2025 Castle Biosciences 1 Empowering people, informing care decisions Fourth Quarter 2024 February 27, 2025 ©2025 Castle Biosciences 2 Disclaimers Forward-Looking Statements This presentation contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, which are subject to the “safe harbor” created by those sections. |
|
| February 27, 2025 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-38 |
|
| February 27, 2025 |
Exhibit 19.1 CASTLE BIOSCIENCES, INC. INSIDER TRADING POLICY INTRODUCTION During the course of your relationship with Castle Biosciences, Inc. (the “Company”), you may receive material information that is not yet publicly available (“material nonpublic information”) about the Company or other publicly traded companies that the Company has business relationships with. Material nonpublic information |
|
| February 27, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 27, 2025 Castle Biosciences, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38984 77-0701774 (state or other jurisdiction of incorporation) (Commiss |
|
| February 27, 2025 |
As filed with the Securities and Exchange Commission on February 27, 2025 As filed with the Securities and Exchange Commission on February 27, 2025 Registration No. |
|
| February 27, 2025 |
Exhibit 107 Calculation of Filing Fee Table Form S-8 Castle Biosciences, Inc. Table 1: Newly Registered Securities Security Type Security Class Title Fee Calculation Rule Amount Registered Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee 1 Equity 2019 Equity Incentive Plan, Common Stock, $0.001 per share Other 1,424,159 $26.55 $37,811,42 |
|
| January 13, 2025 |
EXHIBIT 99.1 Castle Biosciences Announces Preliminary Unaudited Fourth Quarter and Full-Year 2024 Results 2024 total revenue expected to meet or exceed top end of guided range of $320-330 million, at least 50% growth over 2023 Delivered 96,071 total test reports in 2024, an increase of 36% compared to 2023 Year-end 2024 cash, cash equivalents and marketable investment securities expected to be app |
|
| January 13, 2025 |
©2025 Castle Biosciences 1 Empowering people, informing care decisions Preliminary Fourth Quarter and Year-End Results 2024 January 2025 ©2025 Castle Biosciences 2 Disclaimers Forward-Looking Statements This presentation contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, which are subject to the “safe harbor” created by those sections. |
|
| January 13, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 12, 2025 Castle Biosciences, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38984 77-0701774 (state or other jurisdiction of incorporation) (Commissi |
|
| November 14, 2024 |
CSTL / Castle Biosciences, Inc. / GRANAHAN INVESTMENT MANAGEMENT INC/MA Passive Investment SC 13G/A 1 fp0090935-8sc13ga.htm SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULE 13d-1(b), (c), AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(b) (AMENDMENT NO. 1)* Castle Biosciences, Inc. (Name of Issuer) Common Stock, par value $0.001 (Title of Class of Securities) 14843C105 (CUSIP |
|
| November 13, 2024 |
CSTL / Castle Biosciences, Inc. / WASATCH ADVISORS INC Passive Investment SC 13G/A 1 cstl1124.txt SCHEDULE 13G Amendment No. 5 Name of Issuer: Castle Biosciences Inc. Title of Class of Securities: Common Stock CUSIP Number: 14843C105 Item 1: Reporting Person: Wasatch Advisors LP 87-0319391 Item 2: Check Box If Member of Group: Not Applicable Item 3: SEC Use Item 4: Place of Organization: Utah Items 5-8: Number of Shares Owned With: Item 5: Sole Voting Power: 1,826,092 I |
|
| November 4, 2024 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Numbe |
|
| November 4, 2024 |
Exhibit 10.01 CONFIRMATION OF AMENDMENT PROVISIONS THIS CONFIRMATION OF AMENDMENT PROVISIONS (the“Agreement”), made and agreed as of the date of the last party to sign below by and between CASTLE BIOSCIENCES, INC. (“Tenant”) and ACA CONCOURSE EAST UNIT 3 LLC (“Landlord”). WITNESSETH: WHEREAS, Landlord and Tenant entered into a certain Lease Agreement dated April 1, 2022 as amended by the First Ame |
|
| November 4, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 4, 2024 Castle Biosciences, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38984 77-0701774 (state or other jurisdiction of incorporation) (Commissi |
|
| November 4, 2024 |
Exhibit 99.1 Castle Biosciences Reports Third Quarter 2024 Results Q3 2024 revenue increased 39% over Q3 2023 to $86 million Q3 2024 total test reports increased 41% over Q3 2023 Raising full-year 2024 revenue guidance to $320-330 million from $275-300 million Conference call and webcast today at 4:30 p.m. ET FRIENDSWOOD, Texas - Nov. 4, 2024-Castle Biosciences, Inc. (Nasdaq: CSTL), a company impr |
|
| November 4, 2024 |
©2024 Castle Biosciences 1 Empowering people, informing care decisions Third Quarter 2024 November 4, 2024 ©2024 Castle Biosciences 2 Disclaimers Forward-Looking Statements This presentation contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, which are subject to the “safe harbor” created by those sections. |
|
| November 4, 2024 |
©2024 Castle Biosciences 1 Empowering people, informing care decisions November 2024 ©2024 Castle Biosciences 2 Disclaimers Forward-Looking Statements This presentation contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, which are subject to the “safe harbor” created by those sections. |
|
| August 5, 2024 |
Exhibit 99.1 Castle Biosciences Reports Second Quarter 2024 Results Q2 2024 revenue increased 74% over Q2 2023 to $87 million Q2 2024 total test reports increased 49% over Q2 2023 Raising full-year 2024 revenue guidance to $275-300 million from $255-265 million Conference call and webcast today at 4:30 p.m. ET FRIENDSWOOD, Texas - Aug. 5, 2024-Castle Biosciences, Inc. (Nasdaq: CSTL), a company imp |
|
| August 5, 2024 |
©2024 Castle Biosciences 1 Empowering people, informing care decisions August 2024 ©2024 Castle Biosciences 2 Disclaimers Forward-Looking Statements This presentation contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, which are subject to the “safe harbor” created by those sections. |
|
| August 5, 2024 |
©2024 Castle Biosciences 1 Second Quarter 2024 August 5, 2024 Empowering people, Informing care decisions ©2024 Castle Biosciences 2 Disclaimers Forward-Looking Statements This presentation contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, which are subject to the “safe harbor” created by those sections. |
|
| August 5, 2024 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 00 |
|
| August 5, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 5, 2024 Castle Biosciences, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38984 77-0701774 (state or other jurisdiction of incorporation) (Commission |
|
| August 5, 2024 |
Non-Employee Director Compensation Policy, as amended effective May 31, 2024 Exhibit 10.1 Castle Biosciences, Inc. Non-Employee Director Compensation Policy Adopted: June 8, 2019 Amended: January 28, 2021 Amended January 24, 2022 Amended: January 31, 2023 Amended: May 31, 2024 (the “Effective Date”) Each member of the Board of Directors (the “Board”) of Castle Biosciences, Inc. (the “Company”) who is a non-employee director of the Company (each such member, a “Non-Employee |
|
| July 8, 2024 |
CSTL / Castle Biosciences, Inc. / BlackRock Inc. Passive Investment SC 13G/A 1 us14843c1053070824.txt us14843c1053070824.txt SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No: 3) CASTLE BIOSCIENCES INC - (Name of Issuer) Common Stock - (Title of Class of Securities) 14843C105 - (CUSIP Number) June 30, 2024 - (Date of Event Which Requires Filing of this Statement) Check the appropriate box |
|
| May 24, 2024 |
Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 23, 2024 Castle Biosciences, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38984 77-0701774 (State or other jurisdiction of incorporation) (Commission F |
|
| May 10, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No.) Filed by the Registrant ☒ Filed by a party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)( |
|
| May 2, 2024 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 0 |
|
| May 2, 2024 |
Amended Participation Agreement, dated April 1, 2024, by and between the Company and Tobin Juvenal. Exhibit 10.3 APPENDIX A AMENDED PARTICIPATION AGREEMENT Name: Tobin Juvenal Section 1. ELIGIBILITY. You have been designated as eligible to participate in the Castle Biosciences, Inc. Severance and Change in Control Plan (the “Plan”), a copy of which is attached to this Amended Participation Agreement (the “Participation Agreement”). Capitalized terms not explicitly defined in this Participation A |
|
| May 2, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 2, 2024 Castle Biosciences, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38984 77-0701774 (state or other jurisdiction of incorporation) (Commission Fi |
|
| May 2, 2024 |
Amended Participation Agreement, dated April 2, 2024, by and between the Company and Derek Maetzold. Exhibit 10.5 APPENDIX A AMENDED PARTICIPATION AGREEMENT Name: Derek Maetzold Section 1. ELIGIBILITY. You have been designated as eligible to participate in the Castle Biosciences, Inc. Severance and Change in Control Plan (the “Plan”), a copy of which is attached to this Amended Participation Agreement (the “Participation Agreement”). Capitalized terms not explicitly defined in this Participation |
|
| May 2, 2024 |
Exhibit 10.2 CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL. FIRST AMENDMENT TO LEASE AGREEMENT THIS FIRST AMENDMENT TO LEASE AGREEMENT (this “Amendment”) is made and entered into as of the date of the last party to sign below (the “Effectiv |
|
| May 2, 2024 |
Amended Participation Agreement, dated April 2, 2024, by and between the Company and Frank Stokes. Exhibit 10.6 APPENDIX A AMENDED PARTICIPATION AGREEMENT Name: Franklin Stokes Section 1. ELIGIBILITY. You have been designated as eligible to participate in the Castle Biosciences, Inc. Severance and Change in Control Plan (the “Plan”), a copy of which is attached to this Amended Participation Agreement (the “Participation Agreement”). Capitalized terms not explicitly defined in this Participation |
|
| May 2, 2024 |
Exhibit 10.4 APPENDIX A AMENDED PARTICIPATION AGREEMENT Name: Kristen Oelschlager Section 1. ELIGIBILITY. You have been designated as eligible to participate in the Castle Biosciences, Inc. Severance and Change in Control Plan (the “Plan”), a copy of which is attached to this Amended Participation Agreement (the “Participation Agreement”). Capitalized terms not explicitly defined in this Participa |
|
| May 2, 2024 |
©2024 Castle Biosciences 1 First Quarter 2024 May 2, 2024 Empowering people, Informing care decisions ©2024 Castle Biosciences 2 Disclaimers Forward-Looking Statements This presentation contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, which are subject to the “safe harbor” created by those sections. |
|
| May 2, 2024 |
©2024 Castle Biosciences 1 Empowering people, informing care decisions May 2024 ©2024 Castle Biosciences 2 Disclaimers Forward-Looking Statements This presentation contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, which are subject to the “safe harbor” created by those sections. |
|
| May 2, 2024 |
Exhibit 99.1 Castle Biosciences Reports First Quarter 2024 Results Q1 2024 revenue increased 74% over Q1 2023 to $73 million Q1 2024 total test reports increased 40% over Q1 2023 Raising full-year 2024 revenue guidance to $255-265 million from $235-240 million Conference call and webcast today at 4:30 p.m. ET FRIENDSWOOD, Texas - May 2, 2024-Castle Biosciences, Inc. (Nasdaq: CSTL), a company impro |
|
| April 12, 2024 |
CASTLE BIOSCIENCES, INC. 505 S. Friendswood Drive, Suite 401 Friendswood, Texas 77546 CASTLE BIOSCIENCES, INC. 505 S. Friendswood Drive, Suite 401 Friendswood, Texas 77546 April 12, 2024 Division of Corporation Finance Office of Trade & Services United States Securities and Exchange Commission 100 F Street, N.E. Washington, D.C. 20549 RE: Castle Biosciences, Inc. Registration Statement on Form S-3 File No. 333-277470 Ladies and Gentlemen: Castle Biosciences, Inc. (the “Registrant”) |
|
| April 10, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No.) Filed by the Registrant ☒ Filed by a party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Defini |
|
| April 10, 2024 |
ANNUAL REPORTDear Fellow Stockholders, 2023 was an outstanding year for Castle, marked by strong growth that was propelled by our mission of improving health through innovative tests that guide patient care. |
|
| April 10, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No.) Filed by the Registrant ☒ Filed by a party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)( |
|
| March 27, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 26, 2024 Castle Biosciences, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38984 77-0701774 (state or other jurisdiction of incorporation) (Commission |
|
| March 27, 2024 |
Exhibit 10.1 CERTAIN CONFIDENTIAL PORTIONS OF THIS EXHIBIT HAVE BEEN OMITTED AND REPLACED WITH “[***]”. SUCH IDENTIFIED INFORMATION HAS BEEN EXCLUDED FROM THIS EXHIBIT BECAUSE IT IS (I) NOT MATERIAL AND (II) IS THE TYPE THAT THE REGISTRANT CUSTOMARILY AND ACTUALLY TREATS AS PRIVATE OR CONFIDENTIAL. LOAN AND SECURITY AGREEMENT This LOAN AND SECURITY AGREEMENT (this “Agreement”) is dated as of the E |
|
| March 7, 2024 |
United States securities and exchange commission logo March 7, 2024 Derek Maetzold President and Chief Executive Officer Castle Biosciences Inc. |
|
| February 28, 2024 |
Exhibit 107 Calculation of Filing Fee Table Form S-3 (Form Type) Castle Biosciences, Inc. |
|
| February 28, 2024 |
Form of Debt Securities Warrant Agreement and Warrant Certificate. Exhibit 4.8 CASTLE BIOSCIENCES, INC. AND , AS WARRANT AGENT FORM OF DEBT SECURITIES WARRANT AGREEMENT DATED AS OF CASTLE BIOSCIENCES, INC. FORM OF DEBT SECURITIES WARRANT AGREEMENT THIS DEBT SECURITIES WARRANT AGREEMENT (this “Agreement”), dated as of [•], between Castle Biosciences, Inc., a Delaware corporation (the “Company”), and [•], a [corporation] [national banking association] organized and |
|
| February 28, 2024 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-38 |
|
| February 28, 2024 |
Form of Common Stock Warrant Agreement and Warrant Certificate. EXHIBIT 4.6 CASTLE BIOSCIENCES, INC. AND , AS WARRANT AGENT FORM OF COMMON STOCK WARRANT AGREEMENT DATED AS OF 1 CASTLE BIOSCIENCES, INC. FORM OF COMMON STOCK WARRANT AGREEMENT THIS COMMON STOCK WARRANT AGREEMENT (this “Agreement”), dated as of [•], between Castle Biosciences, Inc., a Delaware corporation (the “Company”), and [•], a [corporation] [national banking association] organized and existi |
|
| February 28, 2024 |
Exhibit 107 Calculation of Filing Fee Table Form S-8 (Form Type) Castle Biosciences, Inc. |
|
| February 28, 2024 |
As filed with the Securities and Exchange Commission on February 28, 2024 S-8 As filed with the Securities and Exchange Commission on February 28, 2024 Registration No. |
|
| February 28, 2024 |
As filed with the Securities and Exchange Commission on February 28, 2024 Table of Contents As filed with the Securities and Exchange Commission on February 28, 2024 Registration No. |
|
| February 28, 2024 |
©2024 Castle Biosciences 1 Fourth Quarter 2023 February 28, 2024 Empowering people, Informing care decisions ©2024 Castle Biosciences 2 Disclaimers Forward-Looking Statements This presentation contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, which are subject to the “safe harbor” created by those sections. |
|
| February 28, 2024 |
Exhibit 4.3 CASTLE BIOSCIENCES, INC., Issuer AND [TRUSTEE], Trustee INDENTURE Dated as of [•], 20 Debt Securities TABLE OF CONTENTS PAGE ARTICLE 1 DEFINITIONS 1 Section 1.01 Definitions of Terms 1 ARTICLE 2 ISSUE, DESCRIPTION, TERMS, EXECUTION, REGISTRATION AND EXCHANGE OF SECURITIES 5 Section 2.01 Designation and Terms of Securities 5 Section 2.02 Form of Securities and Trustee’s Certificate 8 |
|
| February 28, 2024 |
©2024 Castle Biosciences 1 Empowering people, informing care decisions February 2024 ©2024 Castle Biosciences 2 Disclaimers Forward-Looking Statements This presentation contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, which are subject to the “safe harbor” created by those sections. |
|
| February 28, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 28, 2024 Castle Biosciences, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38984 77-0701774 (state or other jurisdiction of incorporation) (Commiss |
|
| February 28, 2024 |
Amendment to Purchase Sale Agreement of Land, dated Exhibit 10.38 Execution Version SECOND AMENDMENT TO COMMERCIAL CONTRACT - UNIMPROVED PROPERTY THIS SECOND AMENDMENT TO COMMERCIAL CONTRACT - UNIMPROVED PROPERTY (this “Second Amendment”) is made and entered into as of January 9, 2024 (the “Effective Date”) by and between HAL B. BOONE, an individual residing in Friendswood, Texas (the “Seller”) and CASTLE BIOSCIENCES, INC., a Delaware corporation, |
|
| February 28, 2024 |
Subsidiaries of the Registrant. Exhibit 21.1 CASTLE BIOSCIENCES, INC. SUBSIDIARIES OF THE REGISTRANT Name of Subsidiary State of Incorporation AltheaDx, Inc. Delaware Cernostics, Inc. Delaware Myriad myPath, LLC Delaware Castle Narnia Way Real Estate Holding 1, LLC Texas |
|
| February 28, 2024 |
Exhibit 10.20 Castle Biosciences, Inc. SEVERANCE AND CHANGE IN CONTROL PLAN EFFECTIVE DATE: November 3, 2023 Section 1. INTRODUCTION. The purpose of this Castle Biosciences, Inc. Severance and Change in Control Plan (the “Plan”) is to provide for severance and/or Change in Control (as defined below) benefits to eligible employees of the Company under circumstances described in the Plan. The Plan f |
|
| February 28, 2024 |
Exhibit 99.1 Castle Biosciences Reports Fourth Quarter and Full-Year 2023 Results Full-year 2023 revenue of $220 million, an increase of 60% compared to 2022 and above previously reported guidance Delivered 70,429 total test reports in 2023, an increase of 59% compared to 2022 Year-end 2023 cash, cash equivalents and marketable investment securities of $243 million Two critical peer-reviewed publi |
|
| February 28, 2024 |
Form of Preferred Stock Warrant Agreement and Warrant Certificate. Exhibit 4.7 CASTLE BIOSCIENCES, INC. AND , AS WARRANT AGENT FORM OF PREFERRED STOCK WARRANT AGREEMENT DATED AS OF CASTLE BIOSCIENCES, INC. FORM OF PREFERRED STOCK WARRANT AGREEMENT THIS PREFERRED STOCK WARRANT AGREEMENT (this “Agreement”), dated as of [•], between Castle Biosciences, Inc., a Delaware corporation (the “Company”), and [•], a [corporation] [national banking association] organized and |
|
| February 28, 2024 |
Castle Biosciences, Inc. Incentive Compensation Recoupment Policy Exhibit 97.1 Castle Biosciences, Inc. Incentive Compensation Recoupment Policy 1. Introduction The Compensation Committee (the “Compensation Committee”) of the Board of Directors (the “Board”) of Castle Biosciences, Inc., a Delaware corporation (the “Company”), has determined that it is in the best interests of the Company and its stockholders to adopt this Incentive Compensation Recoupment Policy |
|
| February 14, 2024 |
CSTL / Castle Biosciences, Inc. / GRANAHAN INVESTMENT MANAGEMENT INC/MA Passive Investment SC 13G 1 fp0086874-12sc13g.htm SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULE 13d-1(b), (c), AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(b) (AMENDMENT NO. 0)* Castle Biosciences, Inc. (Name of Issuer) Common Stock, par value $0.001 (Title of Class of Securities) 14843C105 (CUSIP N |
|
| February 13, 2024 |
CSTL / Castle Biosciences, Inc. / VANGUARD GROUP INC - SCHEDULE 13G/A Passive Investment SC 13G/A 1 tv0550-castlebiosciencesinc.htm SCHEDULE 13G/A SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No.: 1)* Name of issuer: Castle Biosciences Inc Title of Class of Securities: Common Stock CUSIP Number: 14843C105 Date of Event Which Requires Filing of this Statement: December 29, 2023 Check the appropriate box to d |
|
| February 13, 2024 |
CSTL / Castle Biosciences, Inc. / PRINCIPAL GLOBAL INVESTORS Passive Investment SC 13G 1 PGI13G14843C105202312.txt 240.13d-102 Schedule 13G - Information to be included in statements filed pursuant to 240.13d-1(b), (c), and (d) and amendments thereto filed pursuant to 240.13d-2. Securities and Exchange Commission, Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No. ) (Name of Issuer) CASTLE BIOSCIENCES INC (Title of Class of Securities |
|
| February 9, 2024 |
CSTL / Castle Biosciences, Inc. / WASATCH ADVISORS INC Passive Investment SC 13G/A 1 cstl224.txt SCHEDULE 13G Amendment No. 4 Name of Issuer: Castle Biosciences Inc. Title of Class of Securities: Common Stock CUSIP Number: 14843C105 Item 1: Reporting Person: Wasatch Advisors LP 87-0319391 Item 2: Check Box If Member of Group: Not Applicable Item 3: SEC Use Item 4: Place of Organization: Utah Items 5-8: Number of Shares Owned With: Item 5: Sole Voting Power: 2,590,951 It |
|
| January 25, 2024 |
CSTL / Castle Biosciences, Inc. / BlackRock Inc. Passive Investment SC 13G/A 1 us14843c1053012524.txt us14843c1053012524.txt SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No: 2) CASTLE BIOSCIENCES INC - (Name of Issuer) Common Stock - (Title of Class of Securities) 14843C105 - (CUSIP Number) December 31, 2023 - (Date of Event Which Requires Filing of this Statement) Check the appropriate |
|
| January 8, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 7, 2024 Castle Biosciences, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38984 77-0701774 (state or other jurisdiction of incorporation) (Commissio |
|
| January 8, 2024 |
January 8, 2024 Transforming Disease Management 2 Disclaimers This presentation contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, which are subject to the “safe harbor” created by those sections. |
|
| January 8, 2024 |
EXHIBIT 99.1 Castle Biosciences Announces Preliminary Fourth Quarter and Full-Year 2023 Results Expect to deliver 2023 total revenue of more than $210 million, at least 53% growth over 2022 Delivered 70,429 total test reports in 2023, an increase of 59% compared to 2022 Year-end 2023 cash, cash equivalents and marketable investment securities expected to be approximately $243 million FRIENDSWOOD, |
|
| December 4, 2023 |
Castle Biosciences, Inc. 2022 Inducement Plan Exhibit 99.1 Castle Biosciences, Inc. 2022 Inducement Plan Adopted by the Compensation Committee: December 22, 2022 Amended and Restated by the Compensation Committee: November 3, 2023 1. General. (a) Eligible Award Recipients. The only persons eligible to receive grants of Awards under this Plan are individuals who satisfy the standards for inducement grants under Nasdaq Marketplace Rule 5635(c)( |
|
| December 4, 2023 |
As filed with the Securities and Exchange Commission on December 4, 2023 As filed with the Securities and Exchange Commission on December 4, 2023 Registration No. |
|
| December 4, 2023 |
Exhibit 107 Calculation of Filing Fee Table Form S-8 (Form Type) Castle Biosciences, Inc. |
|
| November 9, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 3, 2023 Castle Biosciences, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38984 77-0701774 (state or other jurisdiction of incorporation) (Commissi |
|
| November 2, 2023 |
Exhibit 99.1 Castle Biosciences Reports Third Quarter 2023 Results Q3 2023 revenue increased 66% over Q3 2022 to $61 million Q3 2023 total test reports increased 52% over Q3 2022 Raising full year 2023 revenue guidance to at least $200 million from at least $180 million Conference call and webcast today at 4:30 p.m. ET FRIENDSWOOD, Texas - Nov. 2, 2023-Castle Biosciences, Inc. (Nasdaq: CSTL), a co |
|
| November 2, 2023 |
, 2023, by and between the Registrant and Alturas Siete I, LLC. Exhibit 10.2 SIXTH AMENDMENT TO STANDARD OFFICE LEASE THIS SIXTH AMENDMENT TO STANDARD OFFICE LEASE (this “Sixth Amendment”) is dated August 2, 2023 (the “Amendment Date”), and made by ALTURAS SIETE I, LLC, an Idaho limited liability company (“Landlord”), and Castle Biosciences, Inc., a Delaware corporation (“Tenant”), and amends that certain Standard Office Lease dated October 5, 2015 (the “Origi |
|
| November 2, 2023 |
, 2023, by and between the Registrant and Hal B. Boone. Exhibit 10.3 FIRST AMENDMENT TO COMMERCIAL CONTRACT- UNIMPROVED PROPERTY THIS FIRST AMENDMENT TO COMMERCIAL CONTRACT- UNIMPROVED PROPERTY (this “First Amendment”) is made and entered into as of October 4, 2023 (the “Effective Date”) by and between HAL B. BOONE, an individual residing in Friendswood, Texas (the “Seller”) and CASTLE BIOSCIENCES, INC., a Delaware corporation, or its assigns (the “Buy |
|
| November 2, 2023 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Numbe |
|
| November 2, 2023 |
Exhibit 10.1 COMMERCIAL CONTRACT - UNIMPROVED PROPERTY USE OF THIS FORM BY PERSONS WHO ARE NOT MEMBERS OF THE TEXAS ASSOCIATION OF REALTORS®, INC. IS NOT AUTHORIZED. ©Texas Association of REALTORS®, Inc. 2022 1.PARTIES: Seller agrees to sell and convey to Buyer the Property described in Paragraph 2. Buyer agrees to buy the Property from Seller for the sales price stated in Paragraph 3. The parties |
|
| November 2, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 2, 2023 Castle Biosciences, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38984 77-0701774 (state or other jurisdiction of incorporation) (Commissi |
|
| November 2, 2023 |
November 2023 Transforming Disease Management 2 Disclaimers This presentation contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, which are subject to the “safe harbor” created by those sections. |
|
| August 2, 2023 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 00 |
|
| August 2, 2023 |
exhibit992q223 August 2023 Transforming Disease Management 2 Disclaimers This presentation contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, which are subject to the “safe harbor” created by those sections. |
|
| August 2, 2023 |
Exhibit 99.1 Castle Biosciences Reports Second Quarter 2023 Results Q2 2023 revenue increased 44% over Q2 2022 to $50 million Q2 2023 total test reports increased 52% over Q2 2022 Raising full year 2023 revenue guidance to at least $180 million from $170-180 million Conference call and webcast today at 4:30 p.m. ET FRIENDSWOOD, Texas - Aug. 2, 2023-Castle Biosciences, Inc. (Nasdaq: CSTL), a compan |
|
| August 2, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 2, 2023 Castle Biosciences, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38984 77-0701774 (state or other jurisdiction of incorporation) (Commission |
|
| June 5, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 5, 2023 Castle Biosciences, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38984 77-0701774 (State or other jurisdiction of incorporation) (Commission F |
|
| June 1, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 25, 2023 Castle Biosciences, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38984 77-0701774 (State or other jurisdiction of incorporation) (Commission F |
|
| May 15, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No.) Filed by the Registrant ☒ Filed by a party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)( |
|
| May 3, 2023 |
Exhibit 99.1 Castle Biosciences Reports First Quarter 2023 Results Q1 2023 revenue increased 57% over Q1 2022 to $42 million Q1 2023 total test reports increased 73% over Q1 2022 Reaffirming full-year 2023 revenue is expected to be between $170-180 million Conference call and webcast today at 4:30 p.m. ET FRIENDSWOOD, Texas- May 3, 2023-Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving |
|
| May 3, 2023 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 0 |
|
| May 3, 2023 |
Exhibit 10.4 FOURTH AMENDMENT TO STANDARD OFFICE LEASE (SIETE II - 3707 North 7th Street, Phoenix, Arizona 85014) THIS FOURTH AMENDMENT TO STANDARD OFFICE LEASE (this “Fourth Amendment”) is dated 4/18/2023 (the “Amendment Date”), and made by ALTURAS SIETE II, LLC, an Idaho limited liability company (“Landlord”), and CASTLE BIOSCIENCES, INC., a Delaware corporation (“Tenant”), and amends that certa |
|
| May 3, 2023 |
exhibit992q123 First Quarter 2023 May 3, 2023 Transforming Disease Management 2 This presentation contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, which are subject to the “safe harbor” created by those sections. |
|
| May 3, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 3, 2023 Castle Biosciences, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38984 77-0701774 (state or other jurisdiction of incorporation) (Commission Fi |
|
| April 12, 2023 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitte |
|
| April 12, 2023 |
Annual Report 2022DEAR FELLOW STOCKHOLDERS, 2022 was a year of significant growth and success for Castle, driven by strong execution and our steadfast commitment to improve patient care through our innovative, actionable tests. |
|
| April 12, 2023 |
DEFA14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule |
|
| March 1, 2023 |
Forms of Restricted Stock Unit Grant Notice and Restricted Stock Unit Award Agreement under the Exhibit 99.2 CASTLE BIOSCIENCES, INC. RESTRICTED STOCK UNIT GRANT NOTICE (2022 INDUCEMENT PLAN) Castle Biosciences, Inc. (the “Company”), pursuant to its 2022 Inducement Plan (the “Plan”), hereby awards to Participant a Restricted Stock Unit Award for the number of shares of the Company’s Common Stock (“Restricted Stock Units”) set forth below (the “Award”). The Award is subject to all of the term |
|
| March 1, 2023 |
Castle Biosciences, Inc. 2022 Inducement Plan. Exhibit 99.1 CASTLE BIOSCIENCES, INC. 2022 INDUCEMENT PLAN ADOPTED BY THE COMPENSATION COMMITTEE: DECEMBER 22, 2022 1.GENERAL. (a)Eligible Award Recipients. The only persons eligible to receive grants of Awards under this Plan are individuals who satisfy the standards for inducement grants under Nasdaq Marketplace Rule 5635(c)(4) or 5635(c)(3), if applicable, and the related guidance under Nasdaq |
|
| March 1, 2023 |
Forms of Stock Option Grant Notice, Option Agreement and Notice of Exercise under the Exhibit 99.3 Standard Form CASTLE BIOSCIENCES, INC. STOCK OPTION GRANT NOTICE (2022 INDUCEMENT PLAN) Castle Biosciences, Inc. (the “Company”), pursuant to its 2022 Inducement Plan (the “Plan”), hereby grants to Optionholder an option to purchase the number of shares of the Company’s Common Stock set forth below. This option is subject to all of the terms and conditions as set forth in this Stock O |
|
| March 1, 2023 |
As filed with the Securities and Exchange Commission on February 28, 2023 As filed with the Securities and Exchange Commission on February 28, 2023 Registration No. |
|
| March 1, 2023 |
Exhibit 107 Calculation of Filing Fee Table Form S-8 (Form Type) Castle Biosciences, Inc. |
|
| February 28, 2023 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-38 |
|
| February 28, 2023 |
Exhibit 10.25 FIFTH AMENDMENT TO STANDARD OFFICE LEASE THIS FIFTH AMENDMENT TO STANDARD OFFICE LEASE (this “Fifth Amendment”) is dated 10/24/2022 (the “Amendment Date”), and made by ALTURAS SIETE I, LLC, an Idaho limited liability company (“Landlord”), and CASTLE BIOSCIENCES, INC., a Delaware corporation (“Tenant”), and amends that certain Standard Office Lease dated October 5, 2015 (the “Original |
|
| February 28, 2023 |
Exhibit 10.13 Standard Form CASTLE BIOSCIENCES, INC. STOCK OPTION GRANT NOTICE (2022 INDUCEMENT PLAN) Castle Biosciences, Inc. (the “Company”), pursuant to its 2022 Inducement Plan (the “Plan”), hereby grants to Optionholder an option to purchase the number of shares of the Company’s Common Stock set forth below. This option is subject to all of the terms and conditions as set forth in this Stock |
|
| February 28, 2023 |
Castle Biosciences, Inc. Retirement Policy Approved January 13, 2023 Exhibit 10.16 CASTLE BIOSCIENCES, INC. RETIREMENT POLICY EFFECTIVE DATE: JANUARY 15, 2023 Section 1. INTRODUCTION. The purpose of this Castle Biosciences, Inc. Retirement Policy (the “Policy”) is to provide for certain Retirement (as defined below) and retention benefits to eligible employees of the Company under circumstances described in the Policy. The Policy first became effective on the Effec |
|
| February 28, 2023 |
Exhibit 10.32 COMMERCIAL LEASE AMENDMENT USE OF THIS FORM BY PERSONS WHO ARE NOT MEMBERS OF THE TEXAS ASSOCIATION OF REALTORS®, INC. IS NOT AUTHORIZED. ©Texas Association of REALTORS®, Inc. 2022 AMENDMENT TO THE COMMERCIAL LEASE BETWEEN THE UNDERSIGNED PARTIES CONCERNING THE LEASED PREMISES AT 505 S Friendswood Dr 313, Friendswood, TX 77546 Effective on 1-1-2023 , Landlord and Tenant amend the abo |
|
| February 28, 2023 |
Exhibit 99.1 Castle Biosciences Reports Fourth Quarter and Full-Year 2022 Results Full-year 2022 revenue was up 46% over 2021 to $137 million, meeting top end of guided range Delivered 44,419 total test reports in 2022, an increase of 58% compared to 2021 Full-year 2023 revenue is expected to be between $170-180 million Conference call and webcast today at 4:30 p.m. ET FRIENDSWOOD, Texas- Feb. 28, |
|
| February 28, 2023 |
exhibit992q422 Fourth Quarter 2022 February 28, 2023 Transforming Disease Management 2 This presentation contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, which are subject to the “safe harbor” created by those sections. |
|
| February 28, 2023 |
Castle Biosciences, Inc. 2022 Inducement Plan. Exhibit 10.11 CASTLE BIOSCIENCES, INC. 2022 INDUCEMENT PLAN ADOPTED BY THE COMPENSATION COMMITTEE: DECEMBER 22, 2022 1.GENERAL. (a)Eligible Award Recipients. The only persons eligible to receive grants of Awards under this Plan are individuals who satisfy the standards for inducement grants under Nasdaq Marketplace Rule 5635(c)(4) or 5635(c)(3), if applicable, and the related guidance under Nasdaq |
|
| February 28, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 28, 2023 Castle Biosciences, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38984 77-0701774 (state or other jurisdiction of incorporation) (Commiss |
|
| February 28, 2023 |
Exhibit 107 Calculation of Filing Fee Table Form S-8 (Form Type) Castle Biosciences, Inc. |
|
| February 28, 2023 |
Forms of Restricted Stock Unit Grant Notice and Restricted Stock Unit Award Agreement under the Exhibit 10.12 CASTLE BIOSCIENCES, INC. RESTRICTED STOCK UNIT GRANT NOTICE (2022 INDUCEMENT PLAN) Castle Biosciences, Inc. (the “Company”), pursuant to its 2022 Inducement Plan (the “Plan”), hereby awards to Participant a Restricted Stock Unit Award for the number of shares of the Company’s Common Stock (“Restricted Stock Units”) set forth below (the “Award”). The Award is subject to all of the ter |
|
| February 28, 2023 |
Exhibit 10.14 Castle Biosciences, Inc. Non-Employee Director Compensation Policy Adopted: June 8, 2019 Amended: January 28, 2021 Amended January 24, 2022 Amended: January 31, 2023 (the “Effective Date”) Each member of the Board of Directors (the “Board”) of Castle Biosciences, Inc. (the “Company”) who is a non-employee director of the Company (each such member, a “Non-Employee Director”) will rece |
|
| February 28, 2023 |
As filed with the Securities and Exchange Commission on February 28, 2023 As filed with the Securities and Exchange Commission on February 28, 2023 Registration No. |
|
| February 28, 2023 |
Subsidiaries of the Registrant. Exhibit 21.1 CASTLE BIOSCIENCES, INC. SUBSIDIARIES OF THE REGISTRANT Name of Subsidiary State of Incorporation AltheaDx, Inc. Delaware Cernostics, Inc. Delaware Myriad myPath, LLC Delaware |
|
| February 28, 2023 |
Exhibit 10.29 THIRD AMENDMENT TO STANDARD OFFICE LEASE THIS THIRD AMENDMENT TO STANDARD OFFICE LEASE (this “Third Amendment”) is dated February 9, 2023 (the “Amendment Date”), and made by ALTURAS SIETE II, LLC, an Idaho limited liability company (“Landlord”), and CASTLE BIOSCIENCES, INC., a Delaware corporation (“Tenant”), and amends that certain Standard Office Lease dated December 16, 2019 (the |
|
| February 9, 2023 |
CSTL / Castle Biosciences Inc / VANGUARD GROUP INC - SCHEDULE 13G Passive Investment SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 Name of issuer: Castle Biosciences Inc. Title of Class of Securities: Common Stock CUSIP Number: 14843C105 Date of Event Which Requires Filing of this Statement: December 30, 2022 Check the appropriate box to designate the rule pursuant to which this Schedule is filed: ☒ Rule 13d-1(b) ☐ |
|
| February 9, 2023 |
CSTL / Castle Biosciences Inc / WASATCH ADVISORS INC Passive Investment SC 13G/A 1 cstl223.txt SCHEDULE 13G Amendment No. 3 Name of Issuer: Castle Biosciences Inc. Title of Class of Securities: Common Stock CUSIP Number: 14843C105 Item 1: Reporting Person: Wasatch Advisors LP 87-0319391 Item 2: Check Box If Member of Group: Not Applicable Item 3: SEC Use Item 4: Place of Organization: Utah Items 5-8: Number of Shares Owned With: Item 5: Sole Voting Power: 3,222,562 It |
|
| February 3, 2023 |
CSTL / Castle Biosciences Inc / BlackRock Inc. Passive Investment us14843c1053020323.txt SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No: 1) CASTLE BIOSCIENCES INC - (Name of Issuer) Common Stock - (Title of Class of Securities) 14843C105 - (CUSIP Number) December 31, 2022 - (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuan |
|
| January 20, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 13, 2023 Castle Biosciences, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38984 77-0701774 (state or other jurisdiction of incorporation) (Commissi |
|
| January 9, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 8, 2023 Castle Biosciences, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38984 77-0701774 (state or other jurisdiction of incorporation) (Commissio |
|
| January 9, 2023 |
January 9, 2023 Transforming Disease Management 2 Disclaimers This presentation contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, which are subject to the “safe harbor” created by those sections. |
|
| January 9, 2023 |
EX-99.1 2 cstlprelimresultsq42022.htm EX-99.1 EXHIBIT 99.1 Castle Biosciences Announces Preliminary Fourth Quarter and Full-Year 2022 Results 2022 total revenue expected to meet or exceed top end of guided range of $132–137 million Delivered 44,338 total test reports in 2022, an increase of 58% compared to 2021 Growth of 37% year over year in DecisionDx®-Melanoma test report volume Year-end 2022 c |
|
| December 28, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 22, 2022 Castle Biosciences, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38984 77-0701774 (state or other jurisdiction of incorporation) (Commiss |
|
| December 15, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 9, 2022 Castle Biosciences, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38984 77-0701774 (state or other jurisdiction of incorporation) (Commissi |
|
| November 2, 2022 |
Castle Biosciences Announces Third Quarter 2022 Results Q3 2022 revenue grew by 58% over Q3 2021 to $37. |
|
| November 2, 2022 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2022 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Numbe |
|
| November 2, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 2, 2022 Castle Biosciences, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38984 77-0701774 (state or other jurisdiction of incorporation) (Commissi |
|
| November 2, 2022 |
castlebiosciencesq32022v November 2, 2022 Transforming Disease Management 2 Disclaimers This presentation contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, which are subject to the “safe harbor” created by those sections. |
|
| August 8, 2022 |
A u g u s t 8 , 2 0 2 2 Tra n s fo r m i n g D i s e a s e M a n a g e m e nt D i s c l a i m e rs F O R W A R D - L O O K I N G S T A T E M E N T S This presentation contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, which are subject to the ?safe harbor? created by those sections. |
|
| August 8, 2022 |
Castle Biosciences Reports Second Quarter 2022 Results Q2 2022 revenue increased 53% over Q2 2021 to $34. |
|
| August 8, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 8, 2022 Castle Biosciences, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38984 77-0701774 (state or other jurisdiction of incorporation) (Commission |
|
| August 8, 2022 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2022 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 00 |
|
| June 8, 2022 |
Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 2, 2022 Castle Biosciences, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38984 77-0701774 (State or other jurisdiction of incorporation) (Commission F |
|
| June 6, 2022 |
Exhibit 107 Calculation of Filing Fee Tables Form S-3 (Form Type) Castle Biosciences, Inc. |
|
| June 6, 2022 |
As filed with the Securities and Exchange Commission on June 3, 2022 TABLE OF CONTENTS As filed with the Securities and Exchange Commission on June 3, 2022 Registration No. |
|
| June 3, 2022 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 3, 2022 Castle Biosciences, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38984 77-0701774 (state or other jurisdiction of incorporation) (Commission F |
|
| June 3, 2022 |
CASTLE BIOSCIENCES, INC. UNAUDITED PRO FORMA CONDENSED COMBINED FINANCIAL INFORMATION EXHIBIT 99.1 CASTLE BIOSCIENCES, INC. UNAUDITED PRO FORMA CONDENSED COMBINED FINANCIAL INFORMATION The following unaudited pro forma condensed combined financial information was prepared to give effect to the transaction between Castle Biosciences, Inc. (?Castle? or the ?Company?) and Cernostics, Inc. (?Cernostics?) pursuant to an Agreement and Plan of Merger dated October 18, 2021, as amended (th |
|
| May 9, 2022 |
M ay 9 , 2 0 2 2 Tra n s fo r m i n g D i s e a s e M a n a ge m e nt D i s c l a i m e rs F O R W A R D - L O O K I N G S T A T E M E N T S This presentation contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, which are subject to the ?safe harbor? created by those sections. |
|
| May 9, 2022 |
EXHIBIT 10.3 LEASE AGREEMENT Between ACA CONCOURSE EAST UNIT 3 LLC and CASTLE BIOSCIENCES, INC. Unit 3, Nova Place Concourse, Pittsburgh, Pennsylvania Contents Article I - Premises and Term 1 Section 1.1 - Description of Premises 1 Section 1.2 - Interests Granted With the Premises. 2 Section 1.3 - Term 2 Section 1.4 - Reserved Rights 3 Section 1.5 - Extension Option 3 Article II - Rent 4 Section 2 |
|
| May 9, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 9, 2022 Castle Biosciences, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38984 77-0701774 (state or other jurisdiction of incorporation) (Commission Fi |
|
| May 9, 2022 |
Exhibit 99.1 Castle Biosciences Reports First Quarter 2022 Results Q1 2022 revenue increased 18% over Q1 2021 to $26.9 million Q1 2022 adjusted revenue increased 50% over Q1 2021 to $26.3 million Delivered 8,627 total test reports in Q1 2022, an increase of 68% compared to Q1 2021 DecisionDx-Melanoma test report volume increased 48% over Q1 2021 Conference call and webcast today at 4:30 p.m. ET FR |
|
| May 9, 2022 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2022 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 0 |
|
| May 2, 2022 |
Unregistered Sales of Equity Securities UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 26, 2022 Castle Biosciences, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38984 77-0701774 (State or other jurisdiction of incorporation) (Commission |
|
| April 21, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No.) Filed by the Registrant ? Filed by a party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ? Defini |
|
| April 21, 2022 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No.) Filed by the Registrant ? Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14a |
|
| April 7, 2022 |
Entry into a Material Definitive Agreement UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 1, 2022 Castle Biosciences, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38984 77-0701774 (State or other jurisdiction of incorporation) (Commission |
|
| April 4, 2022 |
Exhibit 2.1 CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL. Execution Version AGREEMENT AND PLAN OF MERGER by and among Castle Biosciences, inc., a Delaware corporation, Acorn Merger Sub, Inc., a Delaware corporation, AltheaDx, Inc., a Delaware |
|
| April 4, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 4, 2022 Castle Biosciences, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38984 77-0701774 (State or other jurisdiction of incorporation) (Commission |
|
| March 17, 2022 |
Entry into a Material Definitive Agreement, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 11, 2022 Castle Biosciences, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38984 77-0701774 (State or other jurisdiction of incorporation) (Commission |
|
| March 17, 2022 |
Exhibit 10.1 FOURTH AMENDMENT TO STANDARD OFFICE LEASE THIS FOURTH AMENDMENT TO STANDARD OFFICE LEASE (this ?Fourth Amendment?) is dated 3/11/2022 (the ?Amendment Date?), and made by ALTURAS SIETE I, LLC, an Idaho limited liability company (?Landlord?), and CASTLE BIOSCIENCES, INC., a Delaware corporation (?Tenant?), and amends that certain Standard Office Lease dated October 5, 2015 (the ?Origina |
|
| February 28, 2022 |
Exhibit 99.1 Castle Biosciences Reports Fourth Quarter and Full-Year 2021 Results Full-year 2021 revenue was up 50% over 2020 to $94.1 million, beating expectations Growth of 55% year over year in total GEP testing volume Full-year 2022 revenue is expected to be between $115-120 million Conference call and webcast today at 4:30 p.m. ET FRIENDSWOOD, Texas- Feb. 28, 2022-Castle Biosciences, Inc. (Na |
|
| February 28, 2022 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ? ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2021 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-38 |
|
| February 28, 2022 |
Exhibit 107 Calculation of Filing Fee Table Form S-8 (Form Type) Castle Biosciences, Inc. |
|
| February 28, 2022 |
F e b r u a r y 2 8 , 2 0 2 2 Tra n s fo r m i n g D i s e a s e M a n a ge m e nt D i s c l a i m e rs F O R W A R D - L O O K I N G S T A T E M E N T S This presentation contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, which are subject to the ?safe harbor? created by those sections. |
|
| February 28, 2022 |
Non-Employee Director Compensation Policy, as amended effective January Exhibit 10.11 Castle Biosciences, Inc. Non-Employee Director Compensation Policy Adopted: June 8, 2019 Amended: January 24, 2022 (the ?Effective Date?) Each member of the Board of Directors (the ?Board?) of Castle Biosciences, Inc. (the ?Company?) who is a non-employee director of the Company (each such member, a ?Non-Employee Director?) will receive the compensation described in this Non-Employee |
|
| February 28, 2022 |
Subsidiaries of the Registrant. Exhibit 21.1 CASTLE BIOSCIENCES, INC. SUBSIDIARIES OF THE REGISTRANT Name of Subsidiary State of Incorporation Myriad myPath, LLC Delaware Cernostics, Inc. Delaware |
|
| February 28, 2022 |
As filed with the Securities and Exchange Commission on February 28, 2022 As filed with the Securities and Exchange Commission on February 28, 2022 Registration No. |
|
| February 28, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 28, 2022 Castle Biosciences, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38984 77-0701774 (state or other jurisdiction of incorporation) (Commiss |
|
| February 11, 2022 |
CSTL / Castle Biosciences Inc / MAETZOLD DEREK J - SC 13G/A Passive Investment SC 13G/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 2)* CASTLE BIOSCIENCES, INC. (Name of Issuer) Common Stock, $0.001 par value per share (Title of Class of Securities) 14843C105 (CUSIP Number) December 31, 2021 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to des |
|
| February 10, 2022 |
CSTL / Castle Biosciences Inc / WASATCH ADVISORS INC Passive Investment SCHEDULE 13G Amendment No. 2 Name of Issuer: Castle Biosciences Inc. Title of Class of Securities: Common Stock CUSIP Number: 14843C105 Item 1: Reporting Person: Wasatch Advisors, Inc. 87-0319391 Item 2: Check Box If Member of Group: Not Applicable Item 3: SEC Use Item 4: Place of Organization: Utah Items 5-8: Number of Shares Owned With: Item 5: Sole Voting Power: 3,116,488 Item 6: Shared Voting |
|
| February 4, 2022 |
CSTL / Castle Biosciences Inc / BlackRock Inc. Passive Investment us14843c1053020422.txt SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No: ) CASTLE BIOSCIENCES INC - (Name of Issuer) Common Stock - (Title of Class of Securities) 14843C105 - (CUSIP Number) December 31, 2021 - (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant |
|
| January 14, 2022 |
Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K/A (Amendment No. 1) CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 2, 2021 Castle Biosciences, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38984 77-0701774 (state or other jurisdiction of inco |
|
| January 14, 2022 |
As filed with the Securities and Exchange Commission on January 14, 2022 TABLE OF CONTENTS As filed with the Securities and Exchange Commission on January 14, 2022 Registration No. |
|
| January 14, 2022 |
CASTLE BIOSCIENCES, INC. UNAUDITED PRO FORMA CONDENSED COMBINED FINANCIAL INFORMATION EXHIBIT 99.2 CASTLE BIOSCIENCES, INC. UNAUDITED PRO FORMA CONDENSED COMBINED FINANCIAL INFORMATION The following unaudited pro forma condensed combined financial information was prepared to give effect to the transaction between Castle Biosciences, Inc. (?Castle? or the ?Company?) and Cernostics, Inc., Inc. (?Cernostics?) pursuant to an Agreement and Plan of Merger dated October 18, 2021, as amend |
|
| January 14, 2022 |
EXHIBIT 99.1 CERNOSTICS, INC. Consolidated Financial Statements for the Nine Months Ended September 30, 2021 (Unaudited) and for the Year Ended December 31, 2020 (Audited) and Independent Accountants? Report CERNOSTICS, INC. TABLE OF CONTENTS Page Independent Accountants' Review Report 1 Independent Auditors' Report 2 Consolidated Financial Statements for the Nine Months Ended September 30, 2021 ( |
|
| January 10, 2022 |
J a n u a r y 1 0 , 2 0 2 2 Tra n s fo r m i n g Pa t i e nt M a n a ge m e nt D i s c l a i m e rs F O R W A R D - L O O K I N G S T A T E M E N T S The information in this presentation contains forward-looking statements and information within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, which are subject to the ?safe harbor? created by those sections. |
|
| January 10, 2022 |
EXHIBIT 99.1 Castle Biosciences Announces Preliminary Fourth Quarter and Full-Year 2021 Results 2021 Estimated revenue is expected to meet or exceed top end of guided range of $89-93 million Delivered 28,118 gene expression profile test reports in 2021, an increase of 55% compared to 2020 Year-end 2021 cash and cash equivalents expected to be approximately $330 million FRIENDSWOOD, Texas- Jan. 10, |
|
| January 10, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 10, 2022 Castle Biosciences, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38984 77-0701774 (state or other jurisdiction of incorporation) (Commissi |
|
| January 5, 2022 |
EMPLOYMENT SEPARATION AGREEMENT EXHIBIT 10.1 EMPLOYMENT SEPARATION AGREEMENT This Separation Agreement (the ?Agreement?) is made and entered into as of 12/29/2021 by Castle Biosciences, Inc. (?Castle?), and Bernhard Spiess (the ?Employee?). WHEREAS, Employee was employed by Castle beginning on or about May 2, 2016 in an at-will employment arrangement; WHEREAS, Employee signed an Employee Proprietary Information Agreement with Ca |
|
| January 5, 2022 |
EX-10.2 3 exhibit102-masterserviceag.htm EX-10.2 CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL. EXHIBIT 10.2 MASTER SERVICES AGREEMENT This Master Services Agreement ("Agreement") is made and entered into as of 12/29/2021 by and between Cas |
|
| January 5, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 29, 2021 Castle Biosciences, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38984 77-0701774 (state or other jurisdiction of incorporation) (Commiss |
|
| December 6, 2021 |
Exhibit 2.1 CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL. Execution Version AGREEMENT AND PLAN OF MERGER by and among Castle Biosciences, Inc. a Delaware corporation, Space Merger Sub, Inc. a Delaware corporation, Cernostics, Inc., a Delaw |
|
| December 6, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 2, 2021 Castle Biosciences, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38984 77-0701774 (state or other jurisdiction of incorporation) (Commissi |
|
| December 3, 2021 |
Exhibit 10.2 THIRD AMENDMENT TO STANDARD OFFICE LEASE THIS THIRD AMENDMENT TO STANDARD OFFICE LEASE (this ?Third Amendment?) is dated 11/29/2021 (the ?Amendment Date?), and made by ALTURAS SIETE I, LLC, an Idaho limited liability company (?Landlord?), and CASTLE BIOSCIENCES, INC., a Delaware corporation (?Tenant?), and amends that certain Standard Office Lease dated October 5, 2015 (the ?Original |
|
| December 3, 2021 |
Entry into a Material Definitive Agreement, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 29, 2021 Castle Biosciences, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38984 77-0701774 (state or other jurisdiction of incorporation) (Commiss |
|
| December 3, 2021 |
Exhibit 10.1 SECOND AMENDMENT TO STANDARD OFFICE LEASE THIS SECOND AMENDMENT TO STANDARD OFFICE LEASE (this ?Second Amendment?) is dated 11/29/2021 (the ?Amendment Date?), and made by ALTURAS SIETE II, LLC, an Idaho limited liability company (?Landlord?), and CASTLE BIOSCIENCES, INC., a Delaware corporation (?Tenant?), and amends that certain Standard Office Lease dated December 16, 2019 (the ?Ori |
|
| November 8, 2021 |
N o v e m b e r 8 , 2 0 2 1 A p p l y i n g i n n o v a t i v e d i a g n o s t i c s t o i n f o r m d i s e a s e m a n a g e m e n t d e c i s i o n s D i s c l a i m e rs F O R W A R D - L O O K I N G S T A T E M E N T S The information in this presentation contains forward-looking statements and information within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, which are subject to the ?safe harbor? created by those sections. |
|
| November 8, 2021 |
Exhibit 99.1 Castle Biosciences Announces Third Quarter 2021 Results Q3 2021 revenue grew by 54% over the prior year quarter to $23.5 million Q3 2021 total dermatology test report volume of 7,352 On track to achieve 2021 total revenue guidance of $89-93 million Conference call and webcast today at 4:30 p.m. ET FRIENDSWOOD, Texas- Nov. 8, 2021-Castle Biosciences, Inc. (Nasdaq: CSTL), a company appl |
|
| November 8, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 8, 2021 Castle Biosciences, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38984 77-0701774 (state or other jurisdiction of incorporation) (Commissi |
|
| November 8, 2021 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2021 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Numbe |
|
| October 19, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 18, 2021 Castle Biosciences, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38984 77-0701774 (state or other jurisdiction of incorporation) (Commissi |
|
| October 19, 2021 |
Exhibit 99.1 Castle Biosciences to Acquire Cernostics Fuels mid- and long-term growth with TissueCypher? platform enabling GI franchise Acquisition will expand Castle?s estimated U.S. TAM by approximately $1 billion Castle executive management to host conference call and webcast today at 7:30 a.m. ET FRIENDSWOOD, Texas-(BUSINESS WIRE)?Oct. 19, 2021- Castle Biosciences, Inc. (Nasdaq: CSTL), applyin |
|
| October 19, 2021 |
EX-99.2 3 investorpresentationocto.htm EX-99.2 O c t o b e r 1 9 , 2 0 2 1 C e r n o st i c s A c q u i s i t i o n D i s c l a i m e rs F O R W A R D - L O O K I N G S T A T E M E N T S The information in this presentation contains forward-looking statements and information within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act |
|
| September 9, 2021 |
W e l l s F a r g o 2 0 2 1 H e a l t h c a r e C o n f e r e n c e S e p t e m b e r 9 , 2 0 2 1 Tr a n s f o r m i n g t h e m a n a g e m e n t o f d e r m a t o l o g i c c o n d i t i o n s D i s c l a i m e rs F O R W A R D - L O O K I N G S T A T E M E N T S The information in this presentation contains forward looking statements and information within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, which are subject to the ?safe harbor? created by those sections. |
|
| September 9, 2021 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 9, 2021 Castle Biosciences, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38984 77-0701774 (state or other jurisdiction of incorporation) (Commiss |
|
| August 9, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 9, 2021 Castle Biosciences, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38984 77-0701774 (state or other jurisdiction of incorporation) (Commission |
|
| August 9, 2021 |
Consulting Agreement, dated May 7, 2021, by and among the Registrant and Joseph C. Cook III Exhibit 10.1 CONSULTING AGREEMENT THIS CONSULTING AGREEMENT (the ?Agreement?) is made as of May 7, 2021 (the ?Effective Date?) by and between CASTLE BIOSCIENCES, INC., a Delaware corporation (the ?Company?), and JOSEPH C. COOK III, an individual (?Consultant?). The Company desires to benefit from Consultant?s expertise by retaining Consultant as a consultant, and Consultant desires to perform cons |
|
| August 9, 2021 |
EX-99.1 2 exhibit991q22021earningsre.htm EX-99.1 Exhibit 99.1 Castle Biosciences Announces Second Quarter 2021 Results Q2 2021 revenues of $22.8 million, compared to $12.7 million in Q2 2020 Q2 2021 total dermatology test report volume of 6,539 DecisionDx-Melanoma test reports increased 70%, compared to Q2 2020 Raising 2021 Revenue Guidance to $89-93 million from $80-83 million Conference call and |
|
| August 9, 2021 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2021 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 00 |
|
| August 9, 2021 |
A u g u s t 9 , 2 0 2 1 Tr a n s f o r m i n g t h e m a n a g e m e n t o f d e r m a t o l o g i c c a n c e r s a n d o t h e r d e r m a t o l o g i c d i s e a s e s w i t h h i g h u n m e t n e e d D i s c l a i m e rs F O R W A R D - L O O K I N G S T A T E M E N T S The information in this presentation contains forward-looking statements and information within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, which are subject to the ?safe harbor? created by those sections. |
|
| July 16, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 14, 2021 Castle Biosciences, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38984 77-0701774 (state or other jurisdiction of incorporation) (Commission |
|
| June 14, 2021 |
Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 10, 2021 Castle Biosciences, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38984 77-0701774 (state or other jurisdiction of incorporation) (Commission |
